Daniel Salazar, PhD

Daniel Salazar, PhD has over 18 years of experience in the pharmaceutical and biopharmaceutical industries. Daniel began their career in 2002 as an Executive Director and Senior Director of Clinical Pharmacology at Sankyo Pharma Development. In 2006, they were appointed Vice President of Translational Medicine and Clinical Pharmacology at Daiichi Sankyo Pharma Development, where they led a group of 100 scientists and physicians located in the US, Japan, EU, and India. In 2012, they joined Otsuka Pharmaceutical Development & Commercialization, Inc. as Senior Vice President of Translational Medicine & Think Team. From 2014 to 2015, they were a Principal at Drug Development Consulting LLC, a Braintrust Consultant at The NextGen Marketing Group, and Vice President and Director at Brace Pharma Capital. In 2016, they became a Member of the Board of Directors and Senior Vice President of Development at Tyrogenex. In 2017, they joined Vero Biotech as a Board of Managers and in 2018, they were appointed Chief Executive Officer at Rio Biopharmaceuticals Inc.

Daniel Salazar, PhD completed their PhD in Pharmaceutical Science from the University at Buffalo in 1989. Prior to that, they earned an A.B. in Biology from Princeton University in 1978.